Factor XI Inhibitor Abelacimab Cuts Bleeding Risk Across Age Groups in Atrial Fibrillation

METHODOLOGY:

In a prespecified analysis of a phase 2b randomized trial (AZALEA-TIMI 71), researchers compared the risk for bleeding with abelacimab to that with rivaroxaban by age group in patients with AF.
They included 1287 patients with AF at a moderate-to-high risk for stroke, 55.6% of whom were men. The trial ran between March 2021 and September 2023.
Patients were randomly assigned to receive either once-monthly subcutaneous abelacimab (90 mg or 150 mg) or once-daily oral rivaroxaban (20 mg; reduced to 15 mg in those with impaired kidney function).
The primary outcome was major or clinically relevant nonmajor bleeding, with events counted during treatment and up to 60 days after treatment; the median follow-up duration was 2.1 years. Other assessments included gastrointestinal bleeding, ischemic outcomes, and net clinical outcomes.
Researchers stratified patients by age: younger than 75 years and 75 years or older; 49% of patients were aged 75 years or older.

Patients who received either dose of abelacimab had a significantly lower risk for the primary outcome than those who received rivaroxaban, both among those aged 75 years or older (90 mg: hazard ratio [HR], 0.32; 95% CI, 0.17-0.60; 150 mg: HR, 0.40; 95% CI, 0.22-0.73) and those younger than 75 years (90 mg: HR, 0.28; 95% CI, 0.12-0.61; 150 mg: HR, 0.35; 95% CI, 0.17-0.70).
The risk for bleeding tended to increase with advancing age among patients who received rivaroxaban but remained stable across ages among those who received abelacimab.
Absolute risk reductions with abelacimab vs rivaroxaban were greater among patients aged 75 years or older (7.1 and 6.2 events per 100 patient-years for 90 mg and 150 mg, respectively) than among younger patients (4.7 and 4.2 events per 100 patient-years, respectively).
The use of abelacimab reduced the incidence of major bleeding and major gastrointestinal bleeding in both age groups, nearly eliminating the risk for major gastrointestinal bleeding in adults aged 75 years or older. Reductions in net clinical outcome were also noted.

Factor XI Inhibitor Abelacimab Cuts Bleeding Risk Across Age Groups in Atrial Fibrillation Among adults with atrial fibrillation (AF), those who received the factor XI inhibitor abelacimab had a lower risk for major or clinically relevant nonmajor bleeding than those who received the oral anticoagulant rivaroxaban across age groups, with greater absolute risk reductions in older adults.

High Salivary Aldosterone Can Signal Future Heart Disease Researchers cross-sectionally compared the salivary free AldAR among men with coronary heart disease, essential hypertension, and normotension and prospectively evaluated whether the AldAR could predict the risk for coronary heart disease.

Weight Gain Risks: The Ultraprocessed Food Connection Researchers analyzed data from 24,453 Brazilian adults (79.7% women) in the NutriNet Brasil cohort study, who were followed up for a median of 43.6 months, to assess the association between consumption of ultraprocessed foods and weight gain.

Low Vitamin D Levels Signal Increased Heart Risk in Seniors In older adults, lower levels of vitamin D metabolites and periostin, a protein involved in remodelling and repairing tissues, were linked to an increased cardiovascular (CV) risk. Low periostin levels were correlated with low vitamin D levels, and when all three markers were considered together, only the active form of vitamin D independently predicted the CV risk.

Mapping the evidence on mHealth interventions for cardiovascular event care in Africa: a scoping review The burden of cardiovascular disease in Africa is projected to increase significantly over the next decade, placing additional strain on already overburdened healthcare systems. Mobile health (mHealth) technologies represent a promising approach to addressing these challenges. This review analyzes the use of mHealth solutions in cardiovascular care in Africa.